Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

187 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Real-world characteristics of "super-responders" to mepolizumab and benralizumab in severe eosinophilic asthma and eosinophilic granulomatosis with polyangiitis.
Portacci A, Campisi R, Buonamico E, Nolasco S, Pelaia C, Crimi N, Benfante A, Triggiani M, Spadaro G, Caiaffa MF, Scioscia G, Detoraki A, Valenti G, Papia F, Tomasello A, Scichilone N, Pelaia G, Crimi C, Carpagnano GE. Portacci A, et al. Among authors: crimi n. ERJ Open Res. 2023 Oct 30;9(5):00419-2023. doi: 10.1183/23120541.00419-2023. eCollection 2023 Sep. ERJ Open Res. 2023. PMID: 37908397 Free PMC article.
Benralizumab Effectiveness in Severe Eosinophilic Asthma with Co-Presence of Bronchiectasis: A Real-World Multicentre Observational Study.
Campisi R, Nolasco S, Pelaia C, Impellizzeri P, D'Amato M, Portacci A, Ricciardi L, Scioscia G, Crimi N, Scichilone N, Foschino Barbaro MP, Pelaia G, Carpagnano GE, Vatrella A, Crimi C; Southern Italy Network on Severe Asthma Therapy. Campisi R, et al. Among authors: crimi n. J Clin Med. 2023 Jun 9;12(12):3953. doi: 10.3390/jcm12123953. J Clin Med. 2023. PMID: 37373648 Free PMC article.
Effectiveness and safety of anti-IL-5/Rα biologics in eosinophilic granulomatosis with polyangiitis: a two-year multicenter observational study.
Nolasco S, Portacci A, Campisi R, Buonamico E, Pelaia C, Benfante A, Triggiani M, Spadaro G, Caiaffa MF, Scioscia G, Detoraki A, Valenti G, Papia F, Tomasello A, Crimi N, Scichilone N, Pelaia G, Carpagnano GE, Crimi C. Nolasco S, et al. Among authors: crimi n. Front Immunol. 2023 Jun 30;14:1204444. doi: 10.3389/fimmu.2023.1204444. eCollection 2023. Front Immunol. 2023. PMID: 37457743 Free PMC article.
Severe Asthma Standard-of-Care Background Medication Reduction With Benralizumab: ANDHI in Practice Substudy.
Louis R, Harrison TW, Chanez P, Menzella F, Philteos G, Cosio BG, Lugogo NL, de Luiz G, Burden A, Adlington T, Keeling N, Kwiatek J, Garcia Gil E; ANDHI Study Investigators. Louis R, et al. J Allergy Clin Immunol Pract. 2023 Jun;11(6):1759-1770.e7. doi: 10.1016/j.jaip.2023.03.009. Epub 2023 Mar 21. J Allergy Clin Immunol Pract. 2023. PMID: 36948488 Free article.
Real-life effects of dupilumab in patients with severe type 2 asthma, according to atopic trait and presence of chronic rhinosinusitis with nasal polyps.
Pelaia C, Benfante A, Busceti MT, Caiaffa MF, Campisi R, Carpagnano GE, Crimi N, D'Amato M, Foschino Barbaro MP, Maglio A, Minenna E, Nolasco S, Paglino G, Papia F, Pelaia G, Portacci A, Ricciardi L, Scichilone N, Scioscia G, Triggiani M, Valenti G, Vatrella A, Crimi C. Pelaia C, et al. Among authors: crimi n. Front Immunol. 2023 Mar 30;14:1121237. doi: 10.3389/fimmu.2023.1121237. eCollection 2023. Front Immunol. 2023. PMID: 37063895 Free PMC article.
Patients and doctors group meetings: an innovative way to explore severe asthma backstage.
Caminati M, Camiciottoli G, Baiardini I, Antonicelli L, Beghè B, Crimi N, Favero E, Stanziola AA, Valenti G, Visca D, Del Giacco S. Caminati M, et al. Among authors: crimi n. Multidiscip Respir Med. 2022 Sep 5;17:854. doi: 10.4081/mrm.2022.854. eCollection 2022 Jan 12. Multidiscip Respir Med. 2022. PMID: 36158780 Free PMC article.
187 results